Skip to main content
. Author manuscript; available in PMC: 2018 Mar 9.
Published in final edited form as: Cell. 2017 Mar 9;168(6):1041–1052.e18. doi: 10.1016/j.cell.2017.02.011

Figure 6. S4-3a and wild-type SCF induce similar proliferative and radioprotective effects in vivo.

Figure 6

(A) Experimental setup for analysis of hematopoietic recovery after sub-lethal irradiation. Mice received daily i.p. injections of SCF variants at 250 μg/kg or of PBS starting 2 days prior to sub-lethal TBI (450 Rads) and continued for a total of 10 days. Complete blood cell counts (CBC) were analyzed over a 40-day period as indicated. (B–D) Peripheral blood cell counts of (B) hematocrit (HCT), (C) white blood cells (WBC) and (D) platelets (PLT) over time for mice treated with indicated agents. Data represent mean ± SEM and are pooled from two independent experiments (n≥5). %p<0.05 (statistical significance between PBS and SCF) and #p<0.05 (statistical significance between PBS and S4-3a), and ns = not significant (i.e., p>0.05), by unpaired, two-tailed Student’s t test and corrected for multiple comparisons using the Holm-Sidak method. (E) Experimental setup for analyzing SCF prevention of radiation-induced mortality. Injections of 5 mg/kg SCF variants or PBS were administered i.p. at −20, −10, −2, +2 and +4 h of lethal total body irradiation (TBI; 1150 Rads). Survival was monitored daily for 50 days. (F) Survival of mice treated as described in (E). Data are pooled from two independent experiments (n≥7). ***p<0.001, and ns = not significant (i.e., p>0.05), by Log-rank Mantel-Cox test. See also Figure S5.